Dosage and formulation issues: oral vitamin E therapy in children.

2.50
Hdl Handle:
http://hdl.handle.net/10143/110904
Title:
Dosage and formulation issues: oral vitamin E therapy in children.
Authors:
Westergren, Tone; Kalikstad, Betty
Citation:
European journal of clinical pharmacology 2009, 66 (2):109-18
Additional Links:
http://www.ncbi.nlm.nih.gov/sites/entrez

Full metadata record

DC FieldValue Language
dc.contributor.authorWestergren, Toneen
dc.contributor.authorKalikstad, Bettyen
dc.date.accessioned2010-09-09T11:59:29Z-
dc.date.available2010-09-09T11:59:29Z-
dc.date.issued2010-02-
dc.identifier.citationEuropean journal of clinical pharmacology 2009, 66 (2):109-18en
dc.identifier.issn1432-1041-
dc.identifier.pmid19823814-
dc.identifier.doi10.1007/s00228-009-0729-1-
dc.identifier.urihttp://hdl.handle.net/10143/110904-
dc.description.abstractPURPOSE: Oral vitamin E is used in several childhood diseases, but dosage recommendations differ. Few oral products have a marketing authorization for therapeutic use in children. Preliminary data indicate differences in bioavailability among the various vitamin E compounds. Our objective was to review published data on oral vitamin E therapy in neonates and children in order to establish dosage recommendations at a local level. METHODS: A literature search was conducted, including Medline Ovid, EMBASE (1980-Feb 2008), Cochrane databases, product monographs, handbooks, and textbooks. RESULTS: The main vitamin E compounds being used in children are alpha-tocopherol, alpha-tocopheryl acetate, and tocofersolan. The most data are available on tocopheryl acetate, both in neonates and older children. In children with malabsorption disorders, tocofersolan appears to have an increased bioavailability compared to tocopherol or tocopheryl acetate. Published data on pharmacokinetics and dosages for clinical use are few and heterogeneous. No pharmacokinetic studies were found for tocofersolan in neonates and infants. There are few comparative studies on pharmacokinetics, therapeutic use, and adverse drug reactions (ADRs) in children. Dosages used in clinical studies and dosage recommendations in handbooks differ considerably. CONCLUSIONS: The differences in dosing recommendations in children may be due to lack of systematic studies. Existing published data on oral vitamin E do not provide a basis for evaluation of dosage recommendations in children. Comparative clinical studies are required for scientific evaluation of pharmacokinetics, dosage regimens, and efficacy/ADR assessments in children.en
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/sites/entrezen
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Pediatri: 760en
dc.subject.meshAdministration, Oralen
dc.subject.meshAdolescenten
dc.subject.meshChemistry, Pharmaceuticalen
dc.subject.meshChilden
dc.subject.meshChild, Preschoolen
dc.subject.meshClinical Trials as Topicen
dc.subject.meshDose-Response Relationship, Drugen
dc.subject.meshHumansen
dc.subject.meshInfanten
dc.subject.meshInfant, Newbornen
dc.subject.meshPractice Guidelines as Topicen
dc.subject.meshVitamin Een
dc.titleDosage and formulation issues: oral vitamin E therapy in children.en
dc.typeJournal articleen
dc.typepeer revieweden
dc.contributor.departmentRELIS, Regional Medicines Information Center, Oslo University Hospital, Rikshospitalet, Oslo, Norway. tone.westergren@rikshospitalet.noen
dc.identifier.journalEuropean journal of clinical pharmacologyen
All Items in HeRA are protected by copyright, with all rights reserved, unless otherwise indicated.